CINECA IRIS Institutional Research Information System

CHIRICOZZI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.703
EU - Europa 1.628
AS - Asia 879
AF - Africa 170
SA - Sud America 29
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.418
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.573
CN - Cina 425
IT - Italia 407
BG - Bulgaria 298
GB - Regno Unito 298
SE - Svezia 243
VN - Vietnam 179
SG - Singapore 148
CI - Costa d'Avorio 145
CA - Canada 114
FI - Finlandia 77
DE - Germania 76
RU - Federazione Russa 44
AT - Austria 42
JP - Giappone 38
LT - Lituania 27
IE - Irlanda 26
IN - India 24
HK - Hong Kong 18
ES - Italia 17
NL - Olanda 17
MX - Messico 16
TR - Turchia 16
SN - Senegal 15
FR - Francia 11
ID - Indonesia 11
BR - Brasile 10
CH - Svizzera 9
HU - Ungheria 7
EG - Egitto 6
PL - Polonia 6
AR - Argentina 5
AU - Australia 5
RO - Romania 5
CO - Colombia 4
GR - Grecia 4
KR - Corea 4
PH - Filippine 4
UA - Ucraina 4
BO - Bolivia 3
EC - Ecuador 3
EU - Europa 3
MY - Malesia 3
PE - Perù 3
SA - Arabia Saudita 3
ZA - Sudafrica 3
IR - Iran 2
MT - Malta 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
BE - Belgio 1
CL - Cile 1
CZ - Repubblica Ceca 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
LU - Lussemburgo 1
NE - Niger 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 8.418
Salva come PNG Salva come JPEG
Città #
Fairfield 838
Woodbridge 678
Ashburn 503
Houston 476
Ann Arbor 432
Seattle 347
Chandler 307
Sofia 298
Cambridge 293
Wilmington 273
Lancaster 226
Beijing 200
New York 195
Abidjan 145
Princeton 129
Lawrence 111
Medford 107
Ottawa 99
Serra 98
Des Moines 90
Singapore 67
Nanjing 60
Dong Ket 59
San Diego 43
London 41
Florence 39
Redwood City 34
Washington 33
Guangzhou 32
Dearborn 31
Vienna 26
Phoenix 25
Siauliai 22
Milan 21
Nanchang 19
Hong Kong 18
Los Angeles 18
Rome 16
Dakar 15
Kunming 14
Düsseldorf 13
Jiaxing 13
Changsha 12
Hebei 11
Shenyang 11
Chicago 10
Norwalk 10
Bremen 9
Detroit 9
Bologna 7
Shanghai 7
Hefei 6
Kent 6
Oranmore 6
Pisa 6
Berlin 5
Esslingen am Neckar 5
Frankfurt am Main 5
Hangzhou 5
Indiana 5
Jinan 5
Adana 4
Bareggio 4
Budapest 4
Cairo 4
Cuauhtémoc 4
Dallas 4
Empoli 4
Izmir 4
Mexico 4
Quezon City 4
San Francisco 4
Surabaya 4
Tianjin 4
Bogotá 3
Chapel Hill 3
Edinburgh 3
Foligno 3
Fremont 3
Fuzhou 3
Guadalajara 3
Haikou 3
Hanoi 3
Jakarta 3
Kaunas 3
Lima 3
Lucca 3
Montreal 3
Muizenberg 3
Napoli 3
Ogden 3
Orta 3
Patras 3
Raritan 3
Renton 3
Tokyo 3
Wenzhou 3
Yellow Springs 3
Acton 2
Adapazarı 2
Totale 6.772
Salva come PNG Salva come JPEG
Nome #
Trattamento topico delle dermatiti da contatto: validazione scientifica di una crema lenitiva a base di biotina, L-carnitina, pantenolo, α-bisabololo e tocoferolo. [Topical treatment of contact dermatitis with natural active principles] 181
Assessment of disease severity and treatment effectiveness in hidradenitis suppurativa 165
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 145
Nanomedicine in dermatology: Benefits and emerging applications 133
Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review 133
Potential correlation of wound bed score and biomarkers in chronic lower leg wounds: an exploratory study 127
The Quality of Life impairment in Hidradenitis Suppurativa 120
Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. 114
Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). 110
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 110
Deep pulse fractional CO2 laser combined with a radiofrequency system: results of a case series 109
A new therapeutic for the treatment of moderate to severe plaque psoriasis: apremilast 108
Alexithymia affects patients with hidradenitis suppurativa 106
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. 101
A revolutionary therapeutic approach for psoriasis: bispecific biological agents. 101
Optimizing acitretin use in patients with plaque psoriasis 101
Apremilast for the treatment of psoriasis 100
Cutaneous human papillomaviruses as recurrence factor in actinic keratoses 96
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 96
IL-6 as a druggable target in psoriasis: Focus on pustular variants 96
New insights in the pathogenesis of cutaneous autoimmune disorders. 95
Risankizumab for the treatment of moderate to severe psoriasis 95
Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses 94
Long-Term Outcome of Adalimumab in a Young Girl with Hidradenitis Suppurativa 92
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 91
Acne fulminans associated with lymecycline intake: A case report 91
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 91
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 90
Effective topical agents and emerging perspectives in the treatment of psoriasis. 89
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 89
A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents 88
Profile of certolizumab and its potential in the treatment of psoriatic arthritis. 88
Scanning the immunopathogenesis of psoriasis 87
Gene Expression Profiling Associated with the Progression of Classic Kaposi’s Sarcoma. 87
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. 87
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis 86
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. 85
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris 85
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 85
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 85
Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis 84
Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? 84
Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. 84
New topical treatments for psoriasis 83
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 83
Apheresis in the treatment of recalcitrant atopic dermatitis: Case series and review of the literature 82
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. 82
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers. 81
Granuloma annulare: A case treated with infliximab successfully 81
UVA-1 Laser in the Treatment of Palmoplantar Pustular Psoriasis 80
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: Results of a single-centre, retrospective study 80
Tofacitinib for the treatment of moderate-to-severe psoriasis 80
Lasers and Energy Devices for the Skin: Conventional and Unconventional Use 80
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents 79
Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis 78
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 78
Biomolecular index of therapeutic efficacy in psoriasis treated by anti-TNF alpha agents 78
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 77
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. 76
The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies. 76
Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy 76
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 76
Biomarkers for psoriasis skin lesions 76
IL-17 targeted therapies for psoriasis. 75
Emerging applications of nanomedicine in dermatology 75
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 75
Gynecomastia following isotretinoin treatment: a rare endocrine side effect 74
Efficacy and safety of Infliximab in psoriatic patients over the age of 65 73
An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis 72
IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model. 72
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 71
Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study 71
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa 71
PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition 71
Immunologic biomarkers for clinical and therapeutic management of psoriasis 70
Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab. 69
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. 69
Isotretinoin-triggered acne fulminans: a rare, disabling occurrence 69
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. 68
Unconventional Use of Intense Pulsed Light 68
Trattamento topico della xerosi cutanea severa: risultati di uno studio osservazionale. [Topical treatment of severe xerosis: Results of an observational study] 67
Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. 66
Ustekinumab for treatment of plaque psoriasis in patient with Down Syndrome. 66
A giant annular rash in a tuscanian woodman: the many faces of erythema chronicum migrans 65
Elderly psoriatic patients under biological therapies: an Italian experience 64
Adipose tissue response to IL-17 combined with TNF-alpha exposure 63
Use of Vitamins and their Derivates in the Treatment of Cutaneous Disorders. 62
Psoriasis 62
The Hidradenitis Suppurativa (HS) “Multidisciplinary Unit”: a rationale and practical proposal for an organised clinical approach 62
Dusky Red Swelling of the Penis in Association with Fever and Diarrhoea: A Quiz. 59
Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept 59
European consensus statement on phenotypes of pustular psoriasis 58
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 57
The management of moderate-to-severe chronic plaque psoriasis 56
Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice 54
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 54
Potential role of serum amyloid A in hidradenitis suppurativa 54
Diabete mellito e malattie cutanee autoimmuni 52
Dermal CARD14 expression in psoriasis 49
Un nuovo approccio fototerapico alle dermatosi croniche 49
Totale 8.357
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.800 0 159 75 159 225 229 215 198 210 150 147 33
2020/2021818 66 59 50 48 44 54 37 51 84 77 43 205
2021/20221.112 23 42 46 65 230 159 21 81 42 16 45 342
2022/20231.155 159 166 80 62 110 117 16 83 258 5 82 17
2023/2024768 36 39 90 30 110 243 20 42 6 23 14 115
2024/202510 6 4 0 0 0 0 0 0 0 0 0 0
Totale 8.793